Cited by 1Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) ResearchOccupational and environmental lung diseases

Development of a multi-biomarker risk score based on serum proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC)

Schafer, Peter, Rassa, John, Seyda, Agnes, Hersey, Sarah, Eisinger, Dominic, Melin, Jenna, Bencher, Robert, Neighbors, Margaret +17 more·2024·Idiopathic interstitial pneumonias

Abstract

Introduction: PROLIFIC has developed a set of well-qualified assays to measure serum proteins linked to prognosis in idiopathic pulmonary fibrosis (IPF). Aims & Objectives: To select and combine the most prognostic biomarkers into a multi-marker algorithm and risk score. Methods: Concentrations of 12 biomarkers were measured in serum collected from IPF patients at the time of enrollment (baseline) into the Pulmonary Fibrosis Foundation Patient Registry (N=657). Statistical analyses were performed to define a composite binary outcome of reaching an estimated 10% relative decline in % predicted forced vital capacity (FVC), death, or lung transplant in one year. Penalized logistic regression was used to select prognostic biomarkers using the LASSO method. The resulting model was used to derive a risk score which was evaluated by the ROC curve for its prediction ability. All the statistical analyses were adjusted for sex, age, BMI, anti-fibrotic medication, and % predicted DLCO. Results: Five biomarkers (SP-D, sICAM-1, TNC, CXCL13, and MMP-7) were selected to form the risk score, which was significantly associated with the binary outcome (p = 9.30e-07 and AUC= 0.754). The quartiles of the individual risk scores show clear separation among the transplant-free and 10% FVC reduction-free survival rates. Conclusions: A multi-marker algorithm selected important biomarkers that are consistent with the findings from single-marker analyses, and also developed a subject-level prognostic b…

Integrity signals

Registry

Crossref · 10.1183/13993003.congress-2024.pa4257

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SP-D is a key analyte in a platform currently in development by the PROLIFIC consortium, which is on track to gain regulatory approval for the creation of a diagnostic, prognostic, and theragnostic assay for IPF patients.

    “SP-D is a key analyte in a platform currently in development by the PROLIFIC consortium, which is on track to gain regulatory approval for the creation of a diagnostic, prognostic, and theragnostic assay for IPF patients38.”

Cited by

Sorted by citations

Authors
Schafer, P., Rassa, J., Seyda, A., Hersey, S., Eisinger, D., Melin, J., Bencher, R., Neighbors, M., Mouded, M., Turner, S., Decaris, M., Bauer, Y., Nickerson-Nutter, C., Ball, D., Larson, J., Swaney, J., Lim, S., Mackinnon, A., Marabita, F., Mefford, J., Staszak, S., Martin-Schwarze, A., Zheng, Z., Song, P., & Lasky, J.
Affiliations
  • Genentech (US)
  • Pliant (United States) (US)
  • Three Lakes Foundation (US)
  • Gilead Sciences (United States) (US)
  • Pulmonary Fibrosis Foundation (US)
  • University of Michigan (US)
  • Tulane University (US)
Venue
Idiopathic interstitial pneumonias
Published
2024-09-14
Pages
PA4257
ISSN
0903-1936 (ISSN-L)
OpenAlex
W4404097316
Cited by
0
References
0
Type
conference abstract
Language
en
Open access
closed
Locations
European Respiratory Journal (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, serum biomarkers, prognostic risk score, forced vital capacity decline, serum proteins, surfactant protein D, sICAM-1, TNC, CXCL13, MMP-7, LASSO

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review